SHAWN TAPPER: Open Payments
NPI 1558679563 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,197 in 10 payments from 8 companies in 2025. Trend: 2023 $808 · 2024 $907 · 2025 $1,197
Food & beverage: $1,197
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 2 | $240 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $230 |
| Abbott Laboratories | 1 | $138 |
| Madrigal Pharmaceuticals | 1 | $136 |
| Xeris Pharmaceuticals, Inc. | 1 | $135 |
| ABBVIE INC. | 1 | $125 |
| GlaxoSmithKline, LLC. | 1 | $114 |
| Amgen Inc. | 1 | $78 |
Products named: FREESTYLE LIBRE 3, REZDIFFRA, GVOKE HYPOPEN, Vemlidy, SKYRIZI, Descovy, AREXVY, KRYSTEXXA.
Industry payments across NY — which companies pay providers there.
